ADCGEN-04 is a first-in-class Antibody-Drug Conjugate (ADC) developed for the treatment of several solid tumors, targeting a novel and unexplored antigen with no direct competition.

It combines a high-affinity monoclonal antibody (mAb) with a potent cytotoxic payload, linked through a stable and tumor-specific cleavable linker.

*A pre-licensing agreement has been signed with a U.S. company.

CA09 is a TEAD inhibitor targeting a well-established oncogenic pathway involved in cancer development. TEAD is overexpressed in multiple tumors and plays a key role in downstream signaling by enabling coactivators to transmit cellular signals.

CA09 inhibits the YAP/TAZ pathway through a dual mechanism, combining orthosteric and allosteric inhibition via different small molecules.

The compound has shown no major red flags in development, supporting its clinical progression. While several companies are working on TEAD inhibitors, CA09 differentiates itself by focusing on biomarker-driven patient selection, identifying specific mutations for precision oncology applications.

Its target population includes various epithelial tumors, with a primary focus on Head & Neck Cancer and Breast Cancer.

With a global market potential across multiple oncology indications, CA09 represents a promising next-generation TEAD inhibitor with a unique patient selection strategy

CA11-SM is a highly specific PARP1 inhibitor targeting a well-known and validated oncogenic pathway. As a PARP1-specific inhibitor, it disrupts DNA repair mechanisms in cancer cells, leading to tumor cell death.

While the PARP1 target is well-established, its complex nature and the availability of limited resources have resulted in only two development campaigns.

Currently, competition in the PARP1 inhibitor space is limited but expected to grow rapidly, necessitating continuous monitoring of emerging competitors.

Differentiation remains a key challenge, as the best strategy to distinguish PARP inhibitors is still unclear.

Identifying predictive biomarkers will be crucial for patient selection and optimizing clinical success.

CA11-SM is designed to treat various epithelial tumors, offering broad application across multiple oncology indications. With full intellectual property rights secured, the compound holds strong commercial potential in a rapidly expanding global market.

As part of our public-private collaboration program with UCLM for the development of PROTACs and nanomedicines (nanoPROTACs), in vitro assays are currently being conducted on several PROTACs, primarily targeting breast cancer.